Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Seminars in Arthritis & Rheumatism

• Publication date

  2000-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/SARH.2000.16641PMID 11124283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis

  2004cited by this paper
• Etanercept Therapy in Rheumatoid Arthritis

  1999cited by this paper
• Mechanism of action for leflunomide in rheumatoid arthritis.

  1999cited by this paper
• Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

  1999cited by this paper
• Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

  1999cited by this paper
• Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial

  1999cited by this paper
• Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial.

  1999cited by this paper
• Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.

  1999cited by this paper
• US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis.

  1999cited by this paper
• Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.

  1999cited by this paper
• Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.

  1999cited by this paper
• Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis.

  1998cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.

  1996cited by this paper
• Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.

  1996cited by this paper
• The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.

  1996cited by this paper
• DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

  1996cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs and Acute Renal Failure in the Elderly

  1996cited by this paper
• Longterm low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without structural nephropathy.

  1996cited by this paper
• Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry.

  1996cited by this paper
• Guidelines for the management of rheumatoid arthritis: American College of Rheumatology Ad Hoc Committee on Clinical Guidelines

  1996cited by this paper
• Disease-modifying antirheumatic drugs. Potential effects in older patients.

  1995cited by this paper
• Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.

  1995cited by this paper
• Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy.

  1995cited by this paper
• Antimalarial drug induced decrease in creatinine clearance.

  1995cited by this paper
• The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group.

  1995cited by this paper
• Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs.

  1995cited by this paper
• Importance of Ribonucleotide Availability to Proliferating T-lymphocytes from Healthy Humans

  1995cited by this paper
• Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin

  1994cited by this paper
• Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis.

  1994cited by this paper
• Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group.

  1994cited by this paper
• Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis.

  1994cited by this paper
• The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

  1993cited by this paper
• Renal effects of low dose methotrexate in rheumatoid arthritis.

  1993cited by this paper
• The Mechanism of Action of FK‐506 and Cyclosporin A

  1993cited by this paper
• The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials

  1993cited by this paper
• Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients. International Kidney Biopsy Registry of Cyclosporin (Sandimmun) in Autoimmune Diseases.

  1993cited by this paper
• Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group.

  1992cited by this paper
• Complement C4 null alleles as a marker of gold or D-penicillamine toxicity in the treatment of rheumatoid arthritis.

  1992cited by this paper
• Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

  1992cited by this paper
• TNF alpha--a pivotal role in rheumatoid arthritis?

  1992cited by this paper
• Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

  1992cited by this paper
• Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis.

  1992cited by this paper
• Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.

  1992cited by this paper
• The effect of cyclosporin on renal function.

  1992cited by this paper
• Sulfasalazine in early rheumatoid arthritis

  1992cited by this paper
• Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5-year followup.

  1991cited by this paper
• A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis.

  1991cited by this paper
• The effect of age on methotrexate efficacy and toxicity.

  1991cited by this paper
• Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.

  1990cited by this paper
• The natural course of gold and penicillamine nephropathy: a longterm study of 54 patients.

  1989cited by this paper
• Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients.

  1988cited by this paper
• Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study.

  1988cited by this paper
• Natural course of penicillamine nephropathy: a long term study of 33 patients

  1988cited by this paper
• Gold nephropathy.

  1988cited by this paper
• The natural course of gold nephropathy: long term study of 21 patients.

  1987cited by this paper
• Cyclosporin A treatment of refractory rheumatoid arthritis.

  1987cited by this paper
• Penicillamine-induced proteinuria: risk factors.

  1986cited by this paper
• Mild mesangial glomerulopathy--a frequent finding in rheumatoid arthritis patients with hematuria or proteinuria.

  1986cited by this paper
• Renal papillary necrosis due to naproxen.

  1984cited by this paper
• Renal papillary necrosis due to naproxen.

  1984cited by this paper
• Low-dose D-penicillamine therapy in rheumatoid arthritis. A controlled, double-blind clinical trial.

  1983cited by this paper
• Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.

  1983cited by this paper
• Toward an understanding of patient outcome measurement.

  1983cited by this paper
• Long-term effects of azathioprine in rheumatoid arthritis.

  1982cited by this paper
• Efficacy and Toxicity of d‐Penicillamine for Rheumatoid Disease in the Elderly

  1982cited by this paper
• Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities.

  1982cited by this paper
• Low-dose penicillamine treatment of RA. Comparison of 600 mg and 300 mg regimens.

  1982cited by this paper
• Auranofin therapy in rheumatoid arthritis.

  1982cited by this paper
• Auranofin therapy in rheumatoid arthritis.

  1982cited by this paper
• Adverse reactions to D-penicillamine after gold toxicity.

  1980cited by this paper
• The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis.

  1980cited by this paper
• The toxicity pattern of d-penicillamine therapy

  1980cited by this paper
• Adverse Effects of D-Penicillamine in Rheumatoid Arthritis

  1980cited by this paper
• Long term chrysotherapy: incidence of toxicity and efficacy during sequential time periods.

  1979cited by this paper
• Gold nephropathy in juvenile rheumatoid arthritis.

  1979cited by this paper
• Renal vein thrombosis associated with nephrotic syndrome and gold therapy in rheumatoid arthritis.

  1979cited by this paper
• MEMBRANOUS NEPHROPATHY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RELATIONSHIP TO GOLD THERAPY

  1978cited by this paper
• Toxicity of D-penicillamine in rheumatoid arthritis. A report of 63 patients including two with aplastic anemia and one with the nephrotic syndrome.

  1978cited by this paper
• Effect of Penicillamine on the Kidney

  1977cited by this paper
• Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study.

  1976cited by this paper
• Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid patients.

  1976cited by this paper

• Phytochemical, LC‐MS Studies, and Assessment of Antioxidant, Anti‐inflammatory, Hypoglycemic, Anti‐Rheumatoid‐arthritis Potential with Acmella paniculata: In‐Silico and In‐Vitro Appraisal

  2025cites this paper
• Spatiotemporal distributions and regional disparities of rheumatoid arthritis in 953 global to local locations, 1980-2040, with deep learning-empowered forecasts and evaluation of interventional policies' benefits.

  2025cites this paper
• Association between Rheumatoid Arthritis and the Incidence of IgA Nephropathy

  2025cites this paper
• Klasik Tedaviye Dirençli Romatoid Artrit ve Ankilozan Spondilit Hastalarında Tümör Nekroz Faktör Alfa Blokeri Kullanımının Böbrek Fonksiyonları Üzerine Etkisi

  2025cites this paper
• Observational suspected adverse drug reaction profiles of fluoro-pharmaceuticals and potential mimicry of per- and polyfluoroalkyl substances (PFAS) in the United Kingdom

  2025cites this paper
• A Diagnostic and Management Challenge in Severe Fatal Mercury Poisoning Secondary to Homeopathic Medications.

  2025cites this paper
• The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs.

  2025cites this paper
• The Interplay Between Rheumatoid Arthritis and Chronic Kidney Disease: From Mechanisms to Treatment

  2025cites this paper
• A High-Performance Liquid Chromatography Method Development for Leflunomide Analysis and Validation

  2024cites this paper
• Renal manifestations in adult-onset Still’s disease: a systematic review

  2024cites this paper
• [Low-dose methotrexate: Indications and side effects, particularly in cases of diffuse interstitial pneumonia].

  2024cites this paper
• PEGylated lipid polymeric nanoparticles for management of rheumatoid arthritis

  2024cites this paper
• LEFLUNOMIDE TABLET FORMULATION: DEVELOPMENT AND VALIDATION OF AN RP-HPLC TECHNIQUE

  2023cites this paper
• Encapsulation of Ginger Extract in Nanoemulsions: Preparation, Characterization and in vivo Evaluation in Rheumatoid Arthritis.

  2023cites this paper
• Lipid Nano-System Based Topical Drug Delivery for Management of Rheumatoid Arthritis: An Overview

  2023cites this paper
• Occurrence of adverse events associated with the initiation of methotrexate and biologics for the treatment of psoriasis in routine clinical practice

  2023cites this paper
• The Anti-Rheumatic Drug, Leflunomide, Induces Nephrotoxicity in Mice via Upregulation of TGFβ-Mediated p53/Smad2/3 Signaling

  2022cites this paper
• Nierenmanifestationen bei rheumatoider Arthritis und Spondyloarthritiden

  2022cites this paper
• Autoimmune disease and sickle cell anaemia: ‘Intersecting pathways and differential diagnosis’

  2022cites this paper
• Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study

  2022cites this paper
• Kidneys in SARS‐CoV‐2 era: A challenge of multiple faces

  2022cites this paper
• Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice

  2021cites this paper
• Evaluating a Living Donor With Rheumatoid Arthritis for a Recipient With End-Stage Renal Disease From Antineutrophil Cytoplasmic Antibodies Associated Vasculitis

  2021cites this paper
• Adverse Effects of Low-Dose Methotrexate

  2020cites this paper
• Awareness and knowledge of hydroxychloroquine among public

  2020cites this paper
• Prevalence of and factors associated to chronic kidney disease and hypertension in a cohort of children with juvenile idiopathic arthritis

  2020cites this paper
• Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides)

  2020cites this paper
• Macrophage-Assisted Dissolution of Gold Nanoparticles.

  2019cites this paper
• Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy.

  2019cites this paper
• Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis.

  2018influential citation
• Should a patient with rheumatoid arthritis be a kidney donor?

  2018cites this paper
• Renal Involvement in Rheumatic Diseases

  2017cites this paper
• Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease

  2015cites this paper
• BIOCHEMICAL CHANGES IN GOLD KUSHTA INDUCED NEPHROTOXICITY IN RATS

  2015cites this paper
• Kardiovaskularni rizik u bolesnika s autoimunim bolestima i kroničnom bubrežnom bolesti

  2014cites this paper
• Idiopathic membranous nephropathy preceding the onset of rheumatoid arthritis: a case report.

  2013cites this paper
• Renal involvement in autoimmune connective tissue diseases

  2013cites this paper
• Rheumatoid Arthritis with Secondary Amyloidosis and Chronic Kidney Disease with a Good Response to Etanercept

  2013cites this paper
• METHOTREXATE TOXICITY IN RHEUMATOID ARTHRITIS TO SHRINK ON EARLY DIAGNOSIS AND TREATMENT: A PROSPECTIVE OPEN LABEL STUDY

  2013cites this paper
• Metallic gold beads in hyaluronic acid: a novel form of gold-based immunosuppression? Investigations of the immunosuppressive effects of metallic gold on cultured J774 macrophages and on neuronal gene expression in experimental autoimmune encephalomyelitis

  2013cites this paper
• Evaluation of renal function in patients with psoriasis using immunobiologicals

  2013cites this paper
• Evaluation of renal function in patients with psoriasis using immunobiologicals * Avaliação da função renal de pacientes com psoríase em uso de imunobiológicos

  2013cites this paper
• The Development of Targeted Drug Delivery Systems for Rheumatoid Arthritis Treatment

  2012cites this paper
• Metallic gold slows disease progression, reduces cell death and induces astrogliosis while simultaneously increasing stem cell responses in an EAE rat model of multiple sclerosis

  2012cites this paper
• Safe use of antirheumatic agents in patients with comorbidities.

  2012cites this paper
• A Validated Stability Indicating Reversed Phase High Performance Liquid Chromatographic Method of Leflunomide and Characterization of Its Degradation Products through Retro-Synthesis -

  2012cites this paper
• CURRENT CLINICAL STRATEGIES IN RHEUMATOID ARTHRITIS: A REVIEW

  2012cites this paper
• Inflammatory Response to Therapeutic Gold Bead Implantation in Canine Hip Joint Osteoarthritis

  2011cites this paper
• Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis

  2010cites this paper
• EFFECTS OF CELECOXIB AND LEFLUNOMIDE ON PREGNANT ALBINO RATS AND THEIR DELIVERED NEWBORNS: HISTOPATHOLOGICAL STUDY -

  2010cites this paper
• Metallic gold treatment reduces proliferation of inflammatory cells, increases expression of VEGF and FGF, and stimulates cell proliferation in the subventricular zone following experimental traumatic brain injury.

  2009cites this paper
• Use of TNF Inhibitor in Particular Clinical Settings

  2009cites this paper
• TNF‐alpha inhibitors for psoriatic arthritis

  2009cites this paper
• Incidence and prognosis of renal diseases and measurement of renal function in patients with rheumatoid arthritis

  2009cites this paper
• [Renal involvement in patients with rheumatoid arthritis].

  2009cites this paper
• Metallic gold reduces TNFalpha expression, oxidative DNA damage and pro-apoptotic signals after experimental brain injury.

  2009cites this paper
• Gold salts, D-penicillamine and allopurinol

  2008cites this paper
• Development and Validation of LC Method for the Determination of Famciclovir in Pharmaceutical Formulation Using an Experimental Design

  2008cites this paper
• The toxicity and therapeutic index of a methotrexate polymeric compound, D-85

  2008cites this paper
• Development and validation of LC method for the determination of leflunomide in pharmaceutical formulations using an experimental design

  2008cites this paper
• Tai Chi improves pain and functional status in adults with rheumatoid arthritis: results of a pilot single-blinded randomized controlled trial.

  2008cites this paper
• Immunomodulators: interleukins, interferons, and IV immunoglobulin

  2008cites this paper
• Nephrotoxicity of calcineurin and mTOR inhibitors

  2008cites this paper
• Chapter 22 Inflammatory Arthritis, Behçet's Syndrome, and Sarcoidosis

  2007cites this paper
• Rheumatoid arthritis: appropriate treatment in older people

  2007cites this paper
• Advances in immunosuppressive therapy.

  2007cites this paper
• Advances in Immunosuppressive Therapy

  2007cites this paper
• First Latin American position paper on the pharmacological treatment of rheumatoid arthritis.

  2006cites this paper
• Rheumatoid arthritis: acute presentations and urgent complications.

  2006cites this paper
• A case report of D-penicillamine induced focal segmental glomerulonephritis in a patient scleroderma

  2006cites this paper
• Nežádoucí účinky léků používaných v revmatologii a základní principy monitorování jejich bezpečnosti - I. Chorobu modifikující léky revmatoidní artritidy (DMARDs)

  2005cites this paper
• [Renal manifestations of rheumatic diseases].

  2005cites this paper
• Management Issues with Elderly-Onset Rheumatoid Arthritis

  2005cites this paper
• Renale Manifestationen rheumatischer Erkrankungen

  2005cites this paper
• Tacrolimus and Nonsteroidal Anti-Inflammatory Drugs: An Association to Be Avoided

  2005influential citation
• Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis

  2005cites this paper
• Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.

  2004cites this paper
• Benefit/risk of cyclosporine in rheumatoid arthritis.

  2004cites this paper
• Rheumatoid Arthritis and the Kidney: Uneasy Companions

  2004cites this paper
• Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis.

  2004cites this paper
• Effectiveness of psoriatic arthritis therapies.

  2003cites this paper
• Safety of conventional drugs and biologic agents for Rheumatoid Arthritis.

  2003cites this paper
• [Pharmacotherapy of rheumatic diseases in the aged].

  2003cites this paper
• Evaluation and management of psoriatic arthritis: the role of biologic therapy.

  2003cites this paper
• Addressing the safety of anakinra in patients with rheumatoid arthritis.

  2003cites this paper
• Melatonin prevents methotrexate‐induced hepatorenal oxidative injury in rats

  2003cites this paper
• 18. Immune-mediated renal disease.

  2003cites this paper
• Pharmakotherapie rheumatischer Erkrankungen im Alter

  2003cites this paper
• Challenges in assessing costs of rheumatoid arthritis.

  2003cites this paper
• Calcineurin inhibitors and sirolimus

  2003cites this paper
• Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.

  2003cites this paper
• Advances in anti-inflammatory therapy.

  2002cites this paper
• Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials.

  2002cites this paper
• Mechanisms of NSAID-Induced Hepatotoxicityon Nimesulide

  2002cites this paper
• Mechanisms of NSAID-Induced Hepatotoxicity

  2002cites this paper
• Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.

  2002cites this paper
• Modulation of inducible nitric oxide synthase activation by immunosuppressive drugs.

  2001cites this paper